• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Dr Stephen Silberstein on How Patients Are Reacting to CGRP Inhibitors

Video

Stephen Silberstein, MD, director of the Jefferson Headache Center, discusses patient reactions to being prescribed a CGRP inhibitor.

Stephen Silberstein, MD, director of the Jefferson Headache Center, discusses patient reactions to being prescribed a CGRP inhibitor.

Transcript:

How have patients reacted to being prescribed [calcitonin gene-related peptide] CGRP inhibitors?

In contrast to what we believed, patients are calling and rushing into the office to get the CGRP drugs because they're safe, they're effective, [they have] minimal if any side effects, and they don't have to take a pill every day.

Related Videos
Steven Manobianco, MD
Xiaotong Li, PhD, MS, Memorial Sloan Kettering Cancer Center
Dr Amrita Basu
Justin Drake, PhD
Joanna Rhodes, MD, MSCE, director of the lymphoma program at the Rutgers Cancer Institute and the assistant head of lymphoma at Robert Wood Johnson Medical School
Ira Zackon, MD, senior medical director, Ontada
Shayla Bergmann, MD, a clinical professor in pediatric hematology at the Medical University of South Carolina
Erika Hamilton, MD
Ivo Carre, PhD
Andrew Evens, DO, MBA, MSc, deputy director for clinical services and chief physician officer, Rutgers Cancer Institute
Related Content
© 2025 MJH Life Sciences
AJMC®
All rights reserved.